Bridging TP53-mutated myelodysplastic syndrome/acute myeloid leukemia to transplant: is venetoclax part of the answer? [0.03%]
桥联TP53突变的骨髓增生异常综合征/急性髓系白血病移植：벤ETOCLUSAX 是答案的一部分吗？
Peter Zhao,Samuel Urrutia
Peter Zhao
Purpose of review: TP53-mutated myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) remain among the most challenging myeloid malignancies, with poor long-term outcomes despite allogeneic stem cell transplanta...
Bridging TP53-mutated myelodysplastic syndrome/acute myeloid leukemia to transplant: is venetoclax part of the answer? [0.03%]
桥接TP53突变型骨髓增生异常综合征/急性髓系白血病移植：벤ETO克司能成为答案的一部分吗？
Peter Zhao,Samuel Urrutia
Peter Zhao
Purpose of review: TP53-mutated myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) remain among the most challenging myeloid malignancies, with poor long-term outcomes despite allogeneic stem cell transplanta...
Bridging TP53-mutated myelodysplastic syndrome/acute myeloid leukemia to transplant: is venetoclax part of the answer? [0.03%]
桥接TP53突变的骨髓增生异常综合征/急性髓系白血病移植：维奈克拉是答案的一部分？
Peter Zhao,Samuel Urrutia
Peter Zhao
Purpose of review: TP53-mutated myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) remain among the most challenging myeloid malignancies, with poor long-term outcomes despite allogeneic stem cell transplanta...
Maintenance therapy after allogeneic stem cell transplantation for relapse prevention in myeloid malignancies [0.03%]
allo-HSCT后维持治疗预防髓系恶性肿瘤患者复发
Nihar Desai,Ivan Pasic
Nihar Desai
Purpose of review: Relapse remains the leading cause of treatment failure after allogeneic hematopoietic cell transplantation (HCT) for acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS), and outcomes after ...
Maintenance therapy after allogeneic stem cell transplantation for relapse prevention in myeloid malignancies [0.03%]
异基因干细胞移植后维持治疗可预防髓系肿瘤的复发
Nihar Desai,Ivan Pasic
Nihar Desai
Purpose of review: Relapse remains the leading cause of treatment failure after allogeneic hematopoietic cell transplantation (HCT) for acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS), and outcomes after ...
Inflammation as a pleiotropic regulator of megakaryocyte and platelet hemostatic, immune, and metabolic function [0.03%]
炎症作为多效性调节因子调节巨核细胞和血小板的止血、免疫和代谢功能
Guadalupe Rojas-Sanchez,Pavel Davizon-Castillo
Guadalupe Rojas-Sanchez
Purpose of review: During infectious and noninfectious inflammatory diseases, disruption of the immune-hemostatic balance increases both thrombotic and hemorrhagic risk. We propose that this bidirectional dysregulation re...
Augmenting immune reconstitution after adult allo-haematopoietic stem cell transplantation: current developments and modifiable determinants [0.03%]
allo-HSCT后成人免疫重建的增强：当前进展和可改变因素
Sebastian J Grocott,Igor Novitzky-Basso
Sebastian J Grocott
Purpose of review: Immune reconstitution after adult allogeneic haematopoietic stem cell transplantation (allo-HSCT) shapes infection risk, vaccine responsiveness, relapse and nonrelapse mortality. Advances in graft-vs.-h...
Dynamic myeloid suppressor states in cancer and inflammation and their therapeutic potential [0.03%]
癌症和炎症中的动态髓系抑制状态及其治疗潜力
Alexandra Pommier,Jose A Cancelas
Alexandra Pommier
Purpose of review: Myeloid-derived suppressor cells (MDSCs) are central mediators of immune dysregulation in cancer, infection, and inflammatory diseases. This review highlights recent advances redefining MDSCs' biology, ...
Factor XIa inhibition for the prevention of thrombosis: mechanism, clinical trial signals, and indication-specific positioning [0.03%]
因子XIa抑制在血栓预防中的作用：机制、临床试验信号及特定适应症定位
Evan Kidder,Nirav Dhanesha
Evan Kidder
Purpose of review: Factor XI (FXI) and its activated form, factor XIa (FXIa), have emerged as a leading novel anticoagulant target of the past decade. This review summarizes mechanistic and clinical data from 2023 through...